Abstracts tagged "Anti-ACPA"

Abstract Number: 0766 • ACR Convergence 2020
ACPA and Cholesterol Titers as Predictors of Good Clinical Response at One Year in an Argentine Cohort
Rodrigo Garcia Salinas¹, Alvaro Ruta¹, Santiago Ruta¹, Einer Sanchez Prado¹, Jessica Torres Chichande¹ and Sebastian Magri¹, ¹Hospital Italiano La Plata, La Plata, Argentina
Background/Purpose: Autoantibody positivity, erosions, activity level, and functional capacity were classically defined as poor prognosis. Paradoxically, many of them also predict a good response to…
Abstract Number: 0771 • ACR Convergence 2020
Factors Associated to Clinical and Radiographic Disease Progression in Patients with Early RA and First-degree Relatives: A 1-year Follow-up
Consuelo Romero-Sanchez¹, Juan Manuel Bello-Gualtero², Juliette De Avila³, Gloria Lafaurie⁴, Philipe Chalem Choueka⁵, Cesar Pacheco Tena⁶, Sebastian Giraldo-Q⁷, Jeimmy Andrea Chaparro-Sanabria⁸, Alejandro Ramos-Casallas³, Lorena Chila-M³ and Wilson Bautista-Molano⁹, ¹Hospital Militar Central, Rheumatology and Immunology Department, Universidad Militar Nueva Granada / Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada /Universidad El Bosque, Cellular and Molecular Immunology Group -InmuBo-, School of Dentistry, Bogotá D.C., Colombia, ²Hospital Militar Central, Rheumatology and Immunology Department, Universidad Militar Nueva Granada/ Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada, Bogotá D.C., Colombia, ³Universidad El Bosque, Cellular and Molecular Immunology Group -InmuBo-, School of Dentistry, Bogotá D.C., Colombia, ⁴Universidad El Bosque, Basic Oral Research Unit – UIBO, School of Dentistry, Bogotá D.C., Colombia, ⁵Fundacion Instituto de Reumatología Fernando Chalem, Universidad El Rosario, Bogotá D.C., Colombia, ⁶Universidad Autonoma de Chihuahua, Chihuahua, Chihuahua, Mexico, ⁷Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada, Bogota D.C., Colombia, ⁸Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada, Bogotá D.C., Colombia, ⁹University Hospital Fundación Santa Fé de Bogotá and Universidad El Bosque, Bogotá, Colombia
Background/Purpose: In rheumatoid arthritis (RA), autoimmunity towards citrullinated peptides driven the hypothesis, in which periodontal disease (PD) is strongly related to the pathogenesis. Given the…
Abstract Number: 0772 • ACR Convergence 2020
Modification of THP-1 Cells with Malondialdehyde-Acetaldehyde Increases Cellular Calcium Load Rendering Cells Susceptible to Citrullination of Self-Proteins
Nozima Aripova¹, Michael Duryee¹, Xiarepati Tieliwaerdi¹, Xiaoting Jiang¹, Lynell Klassen², James O'Dell¹, Bryant England¹, Ted Mikuls¹ and Geoffrey Thiele¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Univerisity of Nebraska Medical Center, Omaha, NE
Background/Purpose: The post translational modification of self-proteins with malondialdehyde-acetaldehyde (MAA) has been shown to alter protein function and antibodies to MAA are increased in both…
Abstract Number: 1453 • ACR Convergence 2020
A First in Class Therapeutic Nanoparticle for Specific Targeting of Anti-citrullinated Protein Antibody Ameliorates Serum Transfer and Collagen Induced Arthritis
Sangita Khatri¹, Jonas Hansen¹, Mads Clausen¹, Tue Wenzel Kragstrup², Shu-Chen Hung³, Elizabeth Mellins⁴ and Kira Astakhova¹, ¹Technical University of Denmark, Copenhagen, Denmark, ²Aarhus University, Aarhus, Denmark, ³Amgen, Thousand Oaks, ⁴Stanford University, Stanford, CA
Background/Purpose: Rheumatoid arthritis (RA) is an immune mediated inflammatory disease with autoimmune features, including antibodies to citrullinated proteins and peptides (ACPAs). Several in vitro studies…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].